The Effect of Melatonin on Increasing the Health Related Quality of Life in Non-Metastatic Breast Cancer Patients: Three-Year Follow up a Clinical Trial.

Zahra Keshtpour AmlashiFatemeh SheidaRobab AnbiaeeLeili TapakSeyed Rohallah HosseiniHossein MosaedianNastaran Barati

Published in: Integrative cancer therapies (2024)

Long-term use of 18 mg of melatonin for 3 years in patients with non-metastatic breast cancer can lead to an increase in the patients' quality of life.

Keyphrases

metastatic breast cancer
clinical trial
end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
randomized controlled trial
study protocol
open label